CASI Pharmaceuticals (CASI) AI Stock Analysis

• Market Cap: $20.59M
• Dividend Yield: N/A
• Average Volume (3M): 207.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: 11.40%
• EPS Growth: -18.18%
• Country: US
• Employees: 233
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 15,492,681
• 10 Day Avg. Volume: 39,482
• 30 Day Avg. Volume: 207,959
• PEG Ratio: -0.62
• Price to Book (P/B): -2.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.27
• Enterprise Value/Revenue: 0.25
• Enterprise Value/Gross Profit: 2.23
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $2.75
• Price Target Upside: 96.43% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 39 Underperform
• Price Target: $1.50 ▲(7.14%Upside)

CASI Pharmaceuticals is facing severe financial difficulties, reflected in declining revenues and increasing losses, which significantly impact its stock score. Technical analysis supports a bearish outlook, and the lack of profitability is highlighted by a negative P/E ratio. These factors contribute to a weak overall stock score.

Positive Factors

Analyst Recommendation

The analyst's recommendation is to reiterate a buy rating, focusing on the company's potential in its pipeline products and strategic focus after divestment.

Financial Position

The sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.

Product Development

CID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.

Negative Factors

Business Operations

The company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.

Earnings

CASI reported a net loss of $0.69 per share for the quarter, which is higher than the consensus estimated net loss of $0.61 per share.

Revenue

The company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.

CASI Pharmaceuticals Business Overview & Revenue Model

Company Description

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

How the Company Makes Money

CASI Pharmaceuticals generates revenue primarily through the sale and distribution of its approved oncology drugs and related therapeutics. The company's key revenue streams include product sales, licensing agreements, and strategic collaborations with other pharmaceutical companies. CASI leverages its established commercial infrastructure in key markets, particularly in China, to distribute its products. The company's partnerships with global pharmaceutical firms enable it to expand its product offerings and market reach, contributing significantly to its earnings. Additionally, CASI may earn milestone payments and royalties from licensing its technologies and products to third-party companies.

CASI Pharmaceuticals Financial Statement Overview

Summary

CASI Pharmaceuticals faces significant financial challenges. The decline in revenue and increasing losses are concerning, with profitability metrics showing negative trends. The balance sheet reflects high leverage and shrinking equity, while cash flows are under pressure with persistent negative free cash flow. Improving operational efficiency and revenue growth is crucial for financial stability.

Income Statement

CASI Pharmaceuticals has experienced a consistent decline in total revenue, from $43.1M in 2022 to $28.5M in 2024, indicating a negative revenue growth trend. The company also has negative EBIT and net income, leading to negative profit margins. These factors contribute to a weak income statement performance.

Balance Sheet

The balance sheet shows high leverage with a debt-to-equity ratio increasing to 11.96 in 2024, indicating significant financial risk. Stockholders' equity has drastically decreased over the years. However, the company maintains a significant portion of its assets in cash and cash equivalents, which provides some liquidity cushion.

Cash Flow

Cash flow from operations is consistently negative, leading to negative free cash flow. The company's free cash flow has deteriorated over time, growing more negative from $-26.7M in 2022 to $-29.5M in 2024. While financing activities have provided some cash inflow, this is not sustainable long-term. The operating cash flow to net income ratio is poor, reflecting inefficiencies in converting sales into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.27M	28.54M	33.88M	43.11M	30.17M	15.14M
Gross Profit	11.74M	11.15M	20.05M	27.28M	17.61M	5.63M
EBITDA	-31.07M	-34.87M	-21.54M	-24.07M	-32.75M	-31.35M
Net Income	-30.35M	-39.26M	-26.94M	-39.41M	-37.77M	-62.57M
Balance Sheet
Total Assets	63.62M	53.67M	75.27M	96.23M	138.30M	127.73M
Cash, Cash Equivalents and Short-Term Investments	20.81M	16.09M	30.77M	51.34M	48.57M	66.37M
Total Debt	19.12M	22.14M	21.24M	1.34M	2.17M	1.29M
Total Liabilities	49.77M	51.82M	51.10M	29.30M	30.34M	24.16M
Stockholders Equity	13.85M	1.85M	24.16M	44.57M	84.50M	81.54M
Cash Flow
Free Cash Flow	0.00	-29.46M	-22.21M	-26.70M	-42.34M	-45.21M
Operating Cash Flow	0.00	-29.22M	-19.97M	-21.09M	-26.84M	-25.89M
Investing Cash Flow	0.00	11.24M	-9.67M	31.16M	-20.69M	-20.72M
Financing Cash Flow	0.00	15.43M	-907.00K	-3.27M	29.64M	47.15M

CASI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASI, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.47, below the 50-day MA of 1.73, and below the 200-day MA of 3.15, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 39.38 is Neutral, neither overbought nor oversold. The STOCH value of 56.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CASI.

CASI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
MDAI	45 Neutral	$73.12M	―	256.43%	―	238.96%	35.96%
FEMY	44 Neutral	$30.23M	―	-239.87%	―	61.97%	-6.89%
GBIO	42 Neutral	$22.12M	―	-70.06%	―	146.47%	57.85%
PYPD	41 Neutral	$34.95M	―	-853.05%	―	―	34.97%
CLGN	40 Underperform	$17.17M	―	-75.27%	―	-76.73%	-85.83%
CASI	39 Underperform	$20.59M	―	-1094.50%	―	11.40%	-18.18%